ULTRASONIC SAFETY AND THERAPY IN OPHTHAMALOGY

眼科超声安全和治疗

• 批准号: 6518514
• 负责人: Ernest Joseph Feleppa
• 金额: $ 39.36万
• 依托单位: RIVERSIDE RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6518514
• 关键词: athymic mouse; bioimaging /biomedical imaging; biological models; biomedical equipment development; biomedical equipment safety; computer simulation; diagnosis design /evaluation; diagnosis procedure safety; eye disorder diagnosis; eye neoplasms; eye surgery; glaucoma test; laboratory rabbit; mathematical model; miniature swine; neoplasm /cancer therapy; neoplasm /cancer thermotherapy; nonhuman therapy evaluation; noninvasive diagnosis; retina hemorrhage; ultrasonography; ultrasound biological effect; ultrasound therapy

DESCRIPTION (Verbatim from Applicant's Abstract): This program combines biomedical engineering research at Riverside Research Institute (RRI) with biological and medical investigations at the Weill Medical College (WMC) of Cornell University. Its first objective is to develop noninvasive, focussed ultrasound procedures for treating malignant ocular tumors, which threaten life, and vitreous hemorrhages and membranes, which threaten sight. Its second objective is to support the safe use of diagnostic ultrasound techniques that promise fundamental advances in detecting and combating ocular disease. Both objectives involve comprehensive scientif aboutc investigations of how ultrasonic energy can modify the diverse tissues of the eye. Therapy investigations involve the development of novel ultrasonic beams to thermally necrose large segments of tumors before blood-flow cooling occurs. These investigations explore adaptively controlled beams whose geometry will allow the rapid treatment of entire tumor volumes while avoiding collateral damage. Novel concepts using crossed beams are being developed to mechanically disrupt vitreous hemorrhages and membranes, and to hasten their resorption before they lead to tractional retinal detachments and blindness. Monitoring procedures, using advanced diagnostic ultrasound concepts, are being investigated to monitor, and ultimately control, tumor and vitreous treatments. All procedures are thoroughly tested in animal-model experiments. Safety studies are investigating pulsed-Doppler and color-flow imaging of the eye, with particular attention to therrnal damage in the absorptive, avascular lens. Very-high-frequency systems, which can resolve fine-scale (50-llm) structures are also being examined. This program has performed the first study of ocular effects at these high frequencies (near 50 MHz). Research will now evaluate potential risks when these frequencies are used with ultrasonic contrast agents to evaluate ciliary-body perfusion in glaucoma assays. Safety will be determined using calibrated exposures in in-vivo animal eyes and comprehensive follow-up examinations. Results will be disseminated to support continued safety as new systems evolve.

描述（申请人摘要的逐字记录）：该程序结合了 河滨研究所 (RRI) 的生物医学工程研究 威尔医学院 (WMC) 的生物和医学研究 康奈尔大学。其首要目标是开发无创、集中的 用于治疗威胁眼部恶性肿瘤的超声手术 生命、玻璃体出血和玻璃体膜，威胁视力。它的第二个 目标是支持超声诊断技术的安全使用 有望在检测和对抗眼部疾病方面取得根本性进展。两个都 目标涉及全面的科学调查 超声波能量可以改变眼睛的不同组织。 治疗研究涉及新型超声波束的开发 在血流冷却发生之前热坏死大块肿瘤。 这些研究探索了自适应控制梁，其几何形状将 允许快速治疗整个肿瘤体积，同时避免附带损害 损害。使用交叉梁的新颖概念正在开发中，以机械方式 破坏玻璃体出血和玻璃体膜，并加速其吸收 在导致牵引性视网膜脱离和失明之前。监控 使用先进的超声诊断概念的程序正在 研究目的是监测并最终控制肿瘤和玻璃体治疗。 所有程序都经过动物模型实验的彻底测试。 安全性研究正在调查脉冲多普勒和彩色血流成像 眼睛，特别注意吸收性、无血管性的热损伤 镜片。甚高频系统，可以解析精细尺度（50-llm） 结构也正在接受审查。该计划已进行第一项研究 这些高频（接近 50 MHz）的眼部效应。现在将研究 评估这些频率与超声波一起使用时的潜在风险 造影剂在青光眼检测中评估睫状体灌注。安全 将使用体内动物眼睛的校准曝光来确定 全面的后续检查。结果将被传播以支持 随着新系统的发展，持续的安全性。